Ablaze Pharma and Wenjiang District Government of Chengdu jointly signed a strategic agreement during the Conference of Major Advanced Manufacturing Projects by Foreign Direct Investment.
 
Under the agreement, about 26,000㎡ of industrial land was selected in the Chengdu Medical City, with an initial investment of $100 million to build-up an innovative R&D and manufacturing center for targeted radiation therapies, where five anti-tumor varieties are under research at present, varying from Ac-225 to Lu-177.
 
Ablaze Pharma intends to introduce the world-class innovative targeted radiopharmaceutical therapies (TRT) product designs and clinical experiences into Wenjiang District and jointly build-up the industrial chains of innovative radioactive targeted drug together with the industrial advantages of Wenjiang District.
 
“We are deeply impressed by the strong support and recognition to the newly emerging targeted radiopharmaceutical enterprises from the Wenjiang District Government in the city of Chengdu,” said Dr. Alex Qiao, President and CEO of Ablaze Pharmaceuticals, “Ablaze hopes to work with other companies in the park to build an ecosystem of targeted radiopharmaceuticals from early discovery to commercialization with the help of the resource advantages in nuclear science and technologies in Sichuan Province, and to promote the future development and progress of radiopharmaceutical drugs in China.”
 
“Welcome and congratulations to Ablaze Pharma for the deployment of the R&D and manufacturing center in Chengdu Medical City. In next step, Chengdu Medical City will strengthen the investments and talent attractions to optimize the business environment for synergies to Ablaze Pharma and more industrials so as to build-up the leading highland of the domestic radiopharmaceutical industry,” said Li Zhang, Deputy Head Of The Management Committee Of Chengdu Medical City, Head Of The Investment Promotion Bureau.